Status: Recruiting

Extension Study to Evaluate Safety and Tolerability of Oral Dersimelagon (MT-7117) in Subjects With Erythropoietic Protoporphyria (EPP) or X-Linked Protoporphyria (XLP)

To evaluate the long-term safety and tolerability of oral dersimelagon.

Participants needed: 301

Trial details

Phase: Phase 3Age: 12-75Biological sex: AllType: InterventionalSponsor: Tanabe Pharma America, Inc.Updated: Dec 11, 2025Locations: 51

Eligibility criteria

1. Subjects provided written informed consent to participate. For adolescent sub... [+5]

1. History or presence of photodermatoses other than EPP or XLP. [+18]